| 生物活性 |
Byakangelicol is an orally active furanocoumarin capable of crossing the blood-brain barrier that exerts antitumor effects by inducing ROS accumulation, mitochondrial apoptosis, and cell cycle arrest through mechanisms involving upregulation of JNK/p38 and downregulation of signaling pathways such as AKT, ERK, and STAT3, while also downregulating TLR3/TLR4/MyD88/SARM1/NF-κB to reduce microglial activation and neuroinflammation, and effectively disrupting osteoclast activation and inflammatory responses by inhibiting COX-2 expression, modulating macrophage polarization, and suppressing NF-κB signaling, making it applicable for research on liver cancer, ischemic stroke, and periprosthetic osteolysis. |
体外研究 (In Vitro) |
Byakangelicol (20-100 μM; 24-96 h) 对 HepG2、Hep3B 和 Huh-7 肝癌 (HCC) 细胞具有剂量和时间依赖性的细胞毒性,其 IC50 值范围为 49 至 58 μM,而对正常人源细胞 GES-1、IMR-90 和 293T 的细胞毒性较低。 Byakangelicol (49 μM; 12-72 h) 可诱导 HepG2 细胞呈时间依赖性凋亡,凋亡细胞占比提升 30.37%,且该效应可被 NAC 预处理逆转。 Byakangelicol (49 μM; 12-72 h) 可使 HepG2 细胞的线粒体膜电位降低 18.30%。 Byakangelicol (49 μM; 12-72 h) 可在 HepG2 细胞中诱导细胞内 ROS 呈时间依赖性累积。 Byakangelicol (49 μM; 12-72 h) 可将 HepG2 细胞阻滞于 G2/M 期,使该期细胞比例从 18.87%升高至 31.49%,且该效应可被 NAC 预处理逆转。 Byakangelicol (49 μM; 12-72 h) 以时间依赖的方式抑制 HepG2 细胞迁移,且该效应可被 NAC 预处理逆转。 Byakangelicol (49 μM; 12-72 h) 可调控 HepG2 细胞中的蛋白表达,从而诱导线粒体依赖性凋亡、调控 AKT/MAPK/STAT3 通路、诱导 G2/M 期阻滞,并通过 ROS 介导的机制抑制细胞迁移;而预先使用 NAC 或 MAPK 抑制剂可逆转上述作用。 Byakangelicol (0.01-100 μM; 24 h) 在孵育 24 小时后,于 ≤10 μM 的浓度下对 RAW264.7 细胞无毒性,但在 50 和 100 μM 浓度下表现出细胞毒性。 Byakangelicol (5-10 μM) 可浓度依赖性地抑制 RAW264.7 细胞中由 TiPs 刺激、RANKL 诱导的破骨细胞形成,其中 10 μM 的抑制作用强于 5 μM。 Byakangelicol (5-10 μM; 8 days) 可浓度依赖性地抑制 RAW264.7 细胞在牛骨切片上由 TiPs 刺激、RANKL 诱导的骨吸收,其中 10 μM 的抑制作用强于 5 μM。 Byakangelicol (5-10 μM) 可浓度依赖性地抑制经 RANKL 处理的 RAW264.7 细胞中 TiPs 诱导的 COX-2、MMP9 和 NFATc1 蛋白表达上调,其中 10 μM 的抑制作用强于 5 μM。 Byakangelicol (5-10 μM) 可浓度依赖性地抑制经 RANKL 处理的 RAW264.7 细胞中 TiPs 诱导的 IL-1β、TNF-α 和 IL-6 蛋白表达上调,其中 10 μM 的抑制作用强于 5 μM。 Byakangelicol (5-10 μM) 可浓度依赖性地抑制经 RANKL 处理的 RAW264.7 细胞中 TiPs 刺激的 NF-κB 通路激活,其中 10 μM 对 P-P65 和 P-IKBα 的抑制作用强于 5 μM。 Byakangelicol (5-10 μM) 可浓度依赖性地抑制经 RANKL 处理的 RAW264.7 细胞中 TiPs 诱导的 COX-2、MMP9 和 NFATc1 mRNA 表达上调,其中 10 μM 的抑制作用强于 5 μM。 Byakangelicol (5-10 μM) 呈浓度依赖性抑制经 RANKL 处理的 RAW264.7 细胞中 TiPs 诱导的 IL-1β、TNF-α 和 IL-6 mRNA 表达上调,其中 10 μM 的抑制作用强于 5 μM。 Byakangelicol (5-10 μM; 24 h) 可浓度依赖性地抑制 TiPs 诱导的 M1 极化,并恢复经 RANKL 处理的 RAW264.7 细胞中 M2 标记蛋白的表达,其中 10 μM 对 iNOS 的抑制作用强于 5 μM。 Byakangelicol (5-10 μM; 24 h) 可浓度依赖性地抑制 TiPs 诱导的 M1 极化,并恢复经 RANKL 处理的 RAW264.7 细胞中 M2 标志物的 mRNA 表达,其中 10 μM 对 iNOS 的抑制作用强于 5 μM。 Byakangelicol (5-10 μM; 24 h) 可浓度依赖性地抑制 TiPs 刺激的 M1 极化,并恢复经 RANKL 处理的 RAW264.7 细胞中 M2 标志物的荧光强度,其中 10 μM 对 iNOS 的抑制作用强于 5 μM。 Byakangelicol (5-10 μM) 可浓度依赖性地抑制经 RANKL 处理的 RAW264.7 细胞中 TiPs 诱导的 P65 核转位。
Cell Cytotoxicity Assay
| Cell Line: |
HepG2, Hep3B, Huh-7, GES-1, IMR-90, 293T |
| Concentration: |
20, 40, 60, 80, 100 μM |
| Incubation Time: |
24, 48, 72, 96 h |
| Result: |
Showed dose- and time-dependent cytotoxicity against HepG2, Hep3B, and Huh-7 cells, with significantly stronger killing effects than 5-FU. Exhibited IC50 values of 49 μM for HepG2 cells, 52 μM for Hep3B cells, and 58 μM for Huh-7 cells. Showed lower cytotoxicity to normal GES-1, IMR-90, and 293T cells compared to 5-FU. |
Apoptosis Analysis
| Cell Line: |
HepG2 |
| Concentration: |
49 μM |
| Incubation Time: |
12, 24, 48, 72 h |
| Result: |
Increased the percentage of apoptotic HepG2 cells in a time-dependent manner, reaching a 30.37% increase after 72 h of treatment. Reduced the apoptosis rate from 24.57% to 9.87% when cells were pretreated with NAC. |
Cell Cycle Analysis
| Cell Line: |
HepG2 |
| Concentration: |
49 μM; 49 μM with 10 mM NAC pretreatment |
| Incubation Time: |
12, 24, 48, 72 h; 24 h (NAC pretreatment) |
| Result: |
Increased the proportion of HepG2 cells in the G2/M phase in a time-dependent manner, rising from 18.87% to 31.49% after 72 h of treatment. Reversed the G2/M phase proportion increase from 31.35% to 18.72% when cells were pretreated with NAC. |
Cell Migration Assay
| Cell Line: |
HepG2 |
| Concentration: |
49 μM; 49 μM with 10 mM NAC pretreatment |
| Incubation Time: |
12, 24, 48, 72 h; 72 h (NAC pretreatment, wound healing); 24 h (NAC pretreatment, protein analysis) |
| Result: |
Reduced HepG2 cell migration in a time-dependent manner, with migration ability progressively decreasing over 72 h. Accelerated cell migration, reversing the inhibitory effect of Byakangelicol, when cells were pretreated with NAC. |
Western Blot Analysis
| Cell Line: |
HepG2 |
| Concentration: |
49 μM; 49 μM with 10 μM MAPK inhibitors (FR180204, SP600125, SB203580) pretreatment; 49 μM with 10 mM NAC pretreatment |
| Incubation Time: |
12, 24, 48, 72 h; 24 h (MAPK inhibitors pretreatment); 24 h (NAC pretreatment) |
| Result: |
Increased expression of pro-apoptotic proteins cyto-c, Bad, cle-casp-3, and cle-PARP, and decreased expression of anti-apoptotic protein Bcl-2 in a time-dependent manner. Increased phosphorylated JNK and p38 expression, and decreased phosphorylated AKT, ERK, and STAT3 expression in a time-dependent manner. Reversed changes in signaling pathway protein phosphorylation, and reduced cle-casp-3 and cle-PARP expression when cells were pretreated with NAC. Increased expression of p21 and p27, and decreased expression of CDK1/2 and Cyclin B in a time-dependent manner; NAC pretreatment reversed these changes. Decreased phosphorylated AKT and GSK-3β expression, increased E-cadherin expression, and decreased N-cadherin and β-catenin expression in a time-dependent manner; NAC pretreatment reversed these changes. Reversed changes in signaling pathway protein phosphorylation when cells were pretreated with MAPK inhibitors. |
Cell Cytotoxicity Assay
| Cell Line: |
RAW264.7 mouse osteoclast precursor cells |
| Concentration: |
0.01-100 μM |
| Incubation Time: |
24 h |
| Result: |
Exhibited no significant cytotoxicity at concentrations below 10 μM. Significantly reduced cell viability at concentrations of 50 μM and 100 μM. |
Western Blot Analysis
| Cell Line: |
RAW264.7 mouse osteoclast precursor cells stimulated with RANKL and TiPs |
| Concentration: |
5 and 10 μM |
| Incubation Time: |
24 h |
| Result: |
Reversed TiPs-induced increase in iNOS protein expression and decrease in ARG1 protein expression in a concentration-dependent manner. Reduced iNOS expression and restored ARG1 expression at 5 μM and 10 μM. Showed greater inhibition of iNOS expression at 10 μM than at 5 μM. |
Real Time qPCR
| Cell Line: |
RAW264.7 mouse osteoclast precursor cells stimulated with RANKL and TiPs |
| Concentration: |
5 and 10 μM
|
| Incubation Time: |
24 h |
| Result: |
Reversed TiPs-induced increase in iNOS mRNA expression and decrease in ARG1 mRNA expression in a concentration-dependent manner. Reduced iNOS expression and restored ARG1 expression at 5 μM and 10 μM. Showed greater inhibition of iNOS expression at 10 μM than at 5 μM. |
Immunofluorescence
| Cell Line: |
RAW264.7 mouse osteoclast precursor cells stimulated with RANKL and TiPs |
| Concentration: |
5 and 10 μM
|
| Incubation Time: |
24 h |
| Result: |
Reversed TiPs-induced increase in iNOS fluorescence intensity and decrease in ARG1 fluorescence intensity in a concentration-dependent manner. Reduced iNOS fluorescence and restored ARG1 fluorescence at 5 μM and 10 μM. Showed greater inhibition of iNOS fluorescence at 10 μM than at 5 μM. |
|
体内研究 (In Vivo) |
Byakangelicol (25 mg/kg;口服;每日 1 次;术后 30 分钟开始,连续 3 天) 在 25 mg/kg 剂量下对小鼠缺血性卒中发挥更优的神经保护作用,可显著缩小皮质梗死体积,抑制神经元凋亡,改善运动功能,抑制小胶质细胞增殖及促炎极化,通过 TLR3/TLR4/MyD88/SARM1/NF-κB 通路减轻神经炎症,并通过上调内源性抗氧化酶缓解氧化应激。 Byakangelicol (1 mg/kg/天;颅骨局部注射;每周 3 次;共 28 天) 可通过减少破骨细胞形成、恢复骨形态计量学参数正常水平,并将巨噬细胞极化从促炎 M1 表型转向其他方向,有效缓解 TiPs 诱导的雄性 C57BL/6 小鼠颅部假体周围骨溶解,且观察到成熟破骨细胞数量减少近 50%。
| Animal Model: |
ICR (7-week-old, 25-30 g) |
| Dosage: |
10 mg/kg; 25 mg/kg |
| Administration: |
p.o.; once daily; 3 days (starting 30 minutes post-surgery) |
| Result: |
Reduced ischemia-induced cortical infarction volume, with the 25 mg/kg dose showing a more significant reduction in stroke volume percentage compared to vehicle controls. Significantly decreased the number of TUNEL+ apoptotic cells in the infarct core at 25 mg/kg compared to vehicle and 10 mg/kg groups. Improved forelimb dysfunction at 25 mg/kg, as shown by reduced left paw contact asymmetry in the cylinder test and reduced right forelimb foot faults in the grid walking test, compared to vehicle and 10 mg/kg groups. Significantly decreased the number of Iba-1+ microglia and Iba-1+/BrdU+ proliferating microglia, and reduced Iba-1 protein expression in the infarct core at 25 mg/kg compared to vehicle controls. Decreased the number of iNOS+/Iba-1+ pro-inflammatory microglia and increased the number of CD206+/Iba-1+ anti-inflammatory microglia in the infarct core at 25 mg/kg; also reduced iNOS protein and mRNA (iNOS, CD32) levels, and increased CD206 protein and mRNA (CD206, Ym1/2) levels compared to vehicle controls. Reduced protein levels of pro-inflammatory cytokines TNF-α and IL-1β, and increased protein levels of anti-inflammatory cytokines TGF-β and IL-10 in the infarct core at 25 mg/kg compared to vehicle controls. Reduced protein levels of TLR3, TLR4, p-NF-κB, MyD88, and SARM1 in the infarct core at 25 mg/kg compared to vehicle controls. Decreased immunoreactivity of oxidative stress markers 8-OHdG and 4-HNE, and increased immunoreactivity and protein levels of antioxidant enzymes SOD1, SOD2, and GPX1 in the infarct core at 25 mg/kg compared to vehicle controls. |
| Animal Model: |
C57BL/6 (8-week-old male, cranial osteolysis induced by Ti particles implantation on skull surface) |
| Dosage: |
1 mg/kg/day |
| Administration: |
local skull injection; three times weekly; duration of the study |
| Result: |
Increased bone mineral density compared to the TiPs-only group. Restored bone volume per total volume and trabecular number. Reduced the number of lytic pores in calvariae. Attenuated TiPs-induced calvarial erosion. Reduced TRAP-positive mature osteoclasts by nearly 50%. Decreased the number of MMP9- and NFATc1-positive osteoclast marker cells. Suppressed TiPs-induced COX-2 expression. Reduced levels of M1 macrophage markers iNOS and IL-1b. Reversed the TiPs-induced decrease in M2 macrophage marker ARG1 in calvarial tissues. |
|